Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
4
GHRS Quote, Financials, Valuation and Earnings
Last price:
$7.08
Seasonality move
:
13.42%
Day range:
$6.96 - $7.27
52-week range:
$5.08 - $14.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.92x
Volume:
58.6K
Avg. volume:
67.4K
1-year change:
27.5%
Market cap:
$364.2M
Revenue:
--
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingGH Research PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, GH Research PLC has an estimated upside of 346.43% from its current price of $7.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.00.
Fair Value
-
According to the consensus of 0 analysts, GH Research PLC has 346.43% upside to fair value with a price target of -- per share.
GHRS vs. S&P 500
-
Over the past 5 trading days, GH Research PLC has underperformed the S&P 500 by -16.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GH Research PLC does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GH Research PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter GH Research PLC reported revenues of --.
Earnings Growth
-
GH Research PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter GH Research PLC reported earnings per share of -$0.23.
Enterprise value:
214.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$28M | -$39.4M | -$48.5M | -$9.7M | -$12.6M | |
| EBITDA | -$9.9M | -$40.4M | -$40.9M | -$5.6M | -$12M | |
| Diluted EPS | -$0.20 | -$0.79 | -$0.79 | -$0.11 | -$0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $285.6M | $260M | $164M | $154.9M | |
| Total Assets | -- | $285.6M | $260.1M | $232.6M | $199.6M | |
| Current Liabilities | -- | $2M | $3.4M | $6.1M | $9.8M | |
| Total Liabilities | -- | $2M | $3.4M | $6.8M | $10.2M | |
| Total Equity | -- | $283.6M | $256.7M | $225.8M | $189.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.1M | -$32.1M | -$39.9M | -$10.3M | -$12.3M | |
| Cash From Investing | -$68K | -$138.7M | $43.8M | -$8K | $15.3M | |
| Cash From Financing | -$171K | -$163K | -$286K | -$56K | -$60K | |
| Free Cash Flow | -$23.2M | -$32.2M | -$40M | -$10.3M | -$12.3M | |
GHRS
Sector
Market Cap
$364.2M
$45.6M
Price % of 52-Week High
46.7%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
27.51%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.60
200-day SMA
Sell
Level
$10.19
Bollinger Bands (100)
Sell
Level
7.23 - 10.03
Chaikin Money Flow
Sell
Level
-3.5M
20-day SMA
Sell
Level
$8.23
Relative Strength Index (RSI14)
Sell
Level
37.31
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-91.4634
50-day SMA
Sell
Level
$8.39
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Stock Forecast FAQ
In the current month, GHRS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GHRS average analyst price target in the past 3 months is --.
-
Where Will GH Research PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that GH Research PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About GH Research PLC?
Analysts are divided on their view about GH Research PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GH Research PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is GH Research PLC's Price Target?
The price target for GH Research PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GHRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GH Research PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GHRS?
You can purchase shares of GH Research PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GH Research PLC shares.
-
What Is The GH Research PLC Share Price Today?
GH Research PLC was last trading at $7.08 per share. This represents the most recent stock quote for GH Research PLC. Yesterday, GH Research PLC closed at $7.00 per share.
-
How To Buy GH Research PLC Stock Online?
In order to purchase GH Research PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
